Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cancer pill begins first human safety tests

NCT ID NCT07269145

Summary

This is the first time researchers are giving the experimental capsule TQB3122 to people. The main goal is to check how safe it is, what side effects occur, and how the body processes it in adults with advanced solid tumors that have stopped responding to standard treatments. The study will also look for early signs that the drug might help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Friendship Hospital, Capital Medical University

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100050, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Meizhou People's Hospital (Meizhou Academy of Medical Sciences)

    NOT_YET_RECRUITING

    Meizhou, Guangdong, 514031, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Tenth People's Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200072, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sichuan Cancer Hospital

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.